TNF Pharmaceuticals Stock Soars 6.4% on Short Squeeze Speculation

TNF Pharmaceuticals' stock surged 6.4% in pre-market trading on July 29, 2025, driven by speculation of a potential short squeeze and the company's low market capitalization, which offers significant upside potential if ongoing trials prove successful.

TNF Pharmaceuticals has been the subject of recent discussions in the penny stock community, with investors noting the company's low stock price and the potential for substantial gains if its clinical trials yield positive results. The stock's current trading price near all-time lows has attracted attention from traders looking for high-risk, high-reward opportunities.

Analysts have highlighted the company's small market cap as a key factor in its recent price movements. With a market cap of less than $0.15, TNF Pharmaceuticals is considered a penny stock, making it susceptible to volatility and potential short squeezes. Investors are closely monitoring the company's progress in its clinical trials, as successful outcomes could lead to significant price appreciation.